Overview

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This is an open-label phase 1 study with an escalation part and an expansion part.
Phase:
Phase 1
Details
Lead Sponsor:
Abbisko Therapeutics Co, Ltd